Crop Life Science（CLSL）株式概要農薬会社であるクロップ・ライフ・サイエンス社は、インドで様々な農薬製剤の製造、販売、マーケティングを行っている。 詳細CLSL ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績3/6財務の健全性2/6配当金0/6報酬株価収益率（ 12.6 x） Indian市場（ 23.3 x）を下回っています。過去5年間の収益は年間11.9%増加しました。 リスク分析利払いは収益で十分にカバーされない 意味のある時価総額がありません ( ₹736M )すべてのリスクチェックを見るCLSL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹42.9597.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture02b2016201920222025202620282031Revenue ₹2.1bEarnings ₹58.2mAdvancedSet Fair ValueView all narrativesCrop Life Science Limited 競合他社Bhaskar AgrochemicalsSymbol: BSE:524534Market cap: ₹814.8mAmbey LaboratoriesSymbol: NSEI:AMBEYMarket cap: ₹613.7mAristo Bio-Tech and LifescienceSymbol: NSEI:ARISTOMarket cap: ₹786.6mAgro Phos (India)Symbol: NSEI:AGROPHOSMarket cap: ₹608.4m価格と性能株価の高値、安値、推移の概要Crop Life Science過去の株価現在の株価₹42.9552週高値₹62.8052週安値₹39.45ベータ0.371ヶ月の変化-6.63%3ヶ月変化-11.53%1年変化-14.10%3年間の変化n/a5年間の変化n/aIPOからの変化-19.19%最新ニュースお知らせ • May 22Crop Life Science Limited to Report Second Half, 2026 Results on May 26, 2026Crop Life Science Limited announced that they will report second half, 2026 results on May 26, 2026New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Market cap is less than US$10m (₹758.4m market cap, or US$8.10m). Minor Risk Share price has been volatile over the past 3 months (8.9% average weekly change).Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Executive Independent Director Parulben Shah was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Dec 18These 4 Measures Indicate That Crop Life Science (NSE:CLSL) Is Using Debt ExtensivelySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Nov 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹891.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Market cap is less than US$10m (₹891.3m market cap, or US$9.97m).お知らせ • Nov 07Crop Life Science Limited to Report First Half, 2026 Results on Nov 12, 2025Crop Life Science Limited announced that they will report first half, 2026 results on Nov 12, 2025最新情報をもっと見るRecent updatesお知らせ • May 22Crop Life Science Limited to Report Second Half, 2026 Results on May 26, 2026Crop Life Science Limited announced that they will report second half, 2026 results on May 26, 2026New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Market cap is less than US$10m (₹758.4m market cap, or US$8.10m). Minor Risk Share price has been volatile over the past 3 months (8.9% average weekly change).Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Executive Independent Director Parulben Shah was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Dec 18These 4 Measures Indicate That Crop Life Science (NSE:CLSL) Is Using Debt ExtensivelySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Nov 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹891.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Market cap is less than US$10m (₹891.3m market cap, or US$9.97m).お知らせ • Nov 07Crop Life Science Limited to Report First Half, 2026 Results on Nov 12, 2025Crop Life Science Limited announced that they will report first half, 2026 results on Nov 12, 2025お知らせ • Aug 28Crop Life Science Limited, Annual General Meeting, Sep 26, 2025Crop Life Science Limited, Annual General Meeting, Sep 26, 2025, at 15:30 Indian Standard Time.New Risk • Jun 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.0% average weekly change). Profit margins are more than 30% lower than last year (2.6% net profit margin). Market cap is less than US$100m (₹860.4m market cap, or US$10.1m).New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Market cap is less than US$10m (₹836.4m market cap, or US$9.80m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Profit margins are more than 30% lower than last year (2.6% net profit margin).New Risk • Apr 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Market cap is less than US$10m (₹808.2m market cap, or US$9.46m). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Profit margins are more than 30% lower than last year (2.6% net profit margin).お知らせ • Jan 23Crop Life Science Limited Announces Resignation of Sunita Sebastian Gonsalves as Chief Financial Officer, Effective from February 08, 2025Crop Life Science Limited announced that Mrs. Sunita Sebastian Gonsalves, Chief Financial Officer (CFO) & Key Managerial Personnel (KMP) of the company has tendered her resignation vide letter dated January 22, 2025, due to personal reasons and she will be relived from her duties effective from February 08, 2025 after the closing of business hours.分析記事 • Jan 22Crop Life Science's (NSE:CLSL) Returns On Capital Not Reflecting Well On The BusinessIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...New Risk • Nov 16New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.6% Last year net profit margin: 4.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.3x net interest cover). Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹805.6m market cap, or US$9.54m). Minor Risk Profit margins are more than 30% lower than last year (2.6% net profit margin).New Risk • Oct 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹815.0m (US$9.71m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.8x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (26% accrual ratio). Market cap is less than US$10m (₹815.0m market cap, or US$9.71m).お知らせ • Sep 13Crop Life Science Limited Announces Appointment of Miteshkumar Jayrambhai Rajgor as Company SecretaryCrop Life Science Limited informed to the Stock Exchange that Mr. Miteshkumar Jayrambhai Rajgor has been appointed as Company Secretary and Compliance Officer of the Company with effect from 12th September, 2024. The particulars of the appointment of Mr. Miteshkumar Jayrambhai Rajgor as Company Secretary and Compliance Officer of the Company are as under: Brief profile: PAN: EIOPR6997H. Dare of Birth: July 10,1997. Membership No. ACS 70993. Nature of expertise: Secretarial Work.分析記事 • Aug 26Improved Earnings Required Before Crop Life Science Limited (NSE:CLSL) Stock's 25% Jump Looks JustifiedDespite an already strong run, Crop Life Science Limited ( NSE:CLSL ) shares have been powering on, with a gain of 25...分析記事 • Aug 23Does Crop Life Science (NSE:CLSL) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹53.55, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 35x in the Chemicals industry in India.お知らせ • Aug 21Crop Life Science Limited, Annual General Meeting, Sep 21, 2024Crop Life Science Limited, Annual General Meeting, Sep 21, 2024, at 15:30 Indian Standard Time.お知らせ • Jul 31Crop Life Science Limited Appoints Ashish Mahendersingh Chaudhary as Company Secretary and Compliance OfficerCrop Life Science Limited appointed Ms. Ashish Mahendersingh Chaudhary has been appointed as Company Secretary and Compliance Officer of the Company, effective from July 31, 2024. Date of Birth: 08/06/1999.分析記事 • Jul 05Crop Life Science Limited's (NSE:CLSL) Shares Bounce 27% But Its Business Still Trails The MarketCrop Life Science Limited ( NSE:CLSL ) shares have had a really impressive month, gaining 27% after a shaky period...Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹4.02 (vs ₹3.39 in FY 2023)Full year 2024 results: EPS: ₹4.02 (up from ₹3.39 in FY 2023). Revenue: ₹2.01b (up 52% from FY 2023). Net income: ₹60.4m (up 48% from FY 2023). Profit margin: 3.0% (down from 3.1% in FY 2023). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹43.00, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 29x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹38.25, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 28x in the Chemicals industry in India.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended February 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Market cap is less than US$10m (₹781.6m market cap, or US$9.43m). Minor Risk Latest financial reports are more than 6 months old (reported February 2023 fiscal period end).Valuation Update With 7 Day Price Move • Dec 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹48.80, the stock trades at a trailing P/E ratio of 17.6x. Average trailing P/E is 30x in the Chemicals industry in India.お知らせ • Nov 22Crop Life Science Limited, Annual General Meeting, Dec 13, 2023Crop Life Science Limited, Annual General Meeting, Dec 13, 2023, at 11:00 Indian Standard Time. Location: 209, Primate, Near Judges Bunglow Cross Road Bodakdev Ahmedabad India Agenda: To receive,consider and adopt the Audited Standalone Financial Statement of the Company for the Financial Year ended 31st March, 2023 together with report of the Board of Directors & Auditors thereon; to appoint a Director in place of Mr. Chunilal Samajubhai Virolia; to consider and if thought fit to pass the following resolution with or without modification as Special Resolution; to ratify the remuneration of the Cost Auditors for the financial year ending March 31st, 2024; to approve to make investments, give loans, guarantees and provide securities under Section 186 of the Companies Act, 2013; to approve transactions under Section 185 of the Companies Act, 2013; and to Related Party Transaction for The Financial Year 2023-24.お知らせ • Aug 31Crop Life Science Limited has completed an IPO in the amount of INR 267.28 million.Crop Life Science Limited has completed an IPO in the amount of INR 267.28 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,440,000 Price\Range: INR 52 Discount Per Security: INR 0.4888 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 260,000 Price\Range: INR 52 Discount Per Security: INR 0.4888 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,440,000 Price\Range: INR 52 Discount Per Security: INR 0.4888 Transaction Features: Regulation S株主還元CLSLIN ChemicalsIN 市場7D1.1%0.3%0.5%1Y-14.1%-2.9%-0.5%株主還元を見る業界別リターン: CLSL過去 1 年間で-2.9 % の収益を上げたIndian Chemicals業界を下回りました。リターン対市場: CLSLは、過去 1 年間で-0.5 % のリターンを上げたIndian市場を下回りました。価格変動Is CLSL's price volatile compared to industry and market?CLSL volatilityCLSL Average Weekly Movement8.3%Chemicals Industry Average Movement7.3%Market Average Movement7.1%10% most volatile stocks in IN Market10.1%10% least volatile stocks in IN Market4.8%安定した株価: CLSL 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: CLSLの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2006210Rajesh Lunagariyacroplifescience.com農薬会社であるクロップ・ライフ・サイエンス社は、インドで様々な農薬製剤を製造、流通、販売している。殺虫剤、殺菌剤、除草剤、殺草剤からなる農薬、微量肥料、有機バイオ刺激剤とバイオ肥料、植物成長調整剤、粘着付与剤、抗生物質/殺菌剤、土壌植物健康製品を提供している。また、中国、レバノン、パキスタン、バングラデシュ、エジプト、サウジアラビア、オマーン、ネパール、タイ、マレーシア、インドネシア、ケニア、南アフリカ、ブラジル、ナイジェリア、ギニア、コロンビア、アルゼンチンに製品を輸出している。クロップ・ライフ・サイエンス社は2006年に設立され、本社はインドのアーメダバードにある。もっと見るCrop Life Science Limited 基礎のまとめCrop Life Science の収益と売上を時価総額と比較するとどうか。CLSL 基礎統計学時価総額₹736.16m収益（TTM）₹58.24m売上高(TTM)₹2.15b12.6xPER（株価収益率0.3xP/SレシオCLSL は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CLSL 損益計算書（TTM）収益₹2.15b売上原価₹1.54b売上総利益₹607.66mその他の費用₹549.43m収益₹58.24m直近の収益報告Sep 30, 2025次回決算日May 26, 2026一株当たり利益（EPS）3.40グロス・マージン28.32%純利益率2.71%有利子負債／自己資本比率65.3%CLSL の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 14:18終値2026/05/22 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Crop Life Science Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 22Crop Life Science Limited to Report Second Half, 2026 Results on May 26, 2026Crop Life Science Limited announced that they will report second half, 2026 results on May 26, 2026
New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Market cap is less than US$10m (₹758.4m market cap, or US$8.10m). Minor Risk Share price has been volatile over the past 3 months (8.9% average weekly change).
Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Executive Independent Director Parulben Shah was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Dec 18These 4 Measures Indicate That Crop Life Science (NSE:CLSL) Is Using Debt ExtensivelySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Nov 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹891.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Market cap is less than US$10m (₹891.3m market cap, or US$9.97m).
お知らせ • Nov 07Crop Life Science Limited to Report First Half, 2026 Results on Nov 12, 2025Crop Life Science Limited announced that they will report first half, 2026 results on Nov 12, 2025
お知らせ • May 22Crop Life Science Limited to Report Second Half, 2026 Results on May 26, 2026Crop Life Science Limited announced that they will report second half, 2026 results on May 26, 2026
New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Market cap is less than US$10m (₹758.4m market cap, or US$8.10m). Minor Risk Share price has been volatile over the past 3 months (8.9% average weekly change).
Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Executive Independent Director Parulben Shah was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Dec 18These 4 Measures Indicate That Crop Life Science (NSE:CLSL) Is Using Debt ExtensivelySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Nov 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹891.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Market cap is less than US$10m (₹891.3m market cap, or US$9.97m).
お知らせ • Nov 07Crop Life Science Limited to Report First Half, 2026 Results on Nov 12, 2025Crop Life Science Limited announced that they will report first half, 2026 results on Nov 12, 2025
お知らせ • Aug 28Crop Life Science Limited, Annual General Meeting, Sep 26, 2025Crop Life Science Limited, Annual General Meeting, Sep 26, 2025, at 15:30 Indian Standard Time.
New Risk • Jun 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.0% average weekly change). Profit margins are more than 30% lower than last year (2.6% net profit margin). Market cap is less than US$100m (₹860.4m market cap, or US$10.1m).
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Market cap is less than US$10m (₹836.4m market cap, or US$9.80m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Profit margins are more than 30% lower than last year (2.6% net profit margin).
New Risk • Apr 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Market cap is less than US$10m (₹808.2m market cap, or US$9.46m). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Profit margins are more than 30% lower than last year (2.6% net profit margin).
お知らせ • Jan 23Crop Life Science Limited Announces Resignation of Sunita Sebastian Gonsalves as Chief Financial Officer, Effective from February 08, 2025Crop Life Science Limited announced that Mrs. Sunita Sebastian Gonsalves, Chief Financial Officer (CFO) & Key Managerial Personnel (KMP) of the company has tendered her resignation vide letter dated January 22, 2025, due to personal reasons and she will be relived from her duties effective from February 08, 2025 after the closing of business hours.
分析記事 • Jan 22Crop Life Science's (NSE:CLSL) Returns On Capital Not Reflecting Well On The BusinessIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
New Risk • Nov 16New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.6% Last year net profit margin: 4.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.3x net interest cover). Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹805.6m market cap, or US$9.54m). Minor Risk Profit margins are more than 30% lower than last year (2.6% net profit margin).
New Risk • Oct 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹815.0m (US$9.71m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.8x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (26% accrual ratio). Market cap is less than US$10m (₹815.0m market cap, or US$9.71m).
お知らせ • Sep 13Crop Life Science Limited Announces Appointment of Miteshkumar Jayrambhai Rajgor as Company SecretaryCrop Life Science Limited informed to the Stock Exchange that Mr. Miteshkumar Jayrambhai Rajgor has been appointed as Company Secretary and Compliance Officer of the Company with effect from 12th September, 2024. The particulars of the appointment of Mr. Miteshkumar Jayrambhai Rajgor as Company Secretary and Compliance Officer of the Company are as under: Brief profile: PAN: EIOPR6997H. Dare of Birth: July 10,1997. Membership No. ACS 70993. Nature of expertise: Secretarial Work.
分析記事 • Aug 26Improved Earnings Required Before Crop Life Science Limited (NSE:CLSL) Stock's 25% Jump Looks JustifiedDespite an already strong run, Crop Life Science Limited ( NSE:CLSL ) shares have been powering on, with a gain of 25...
分析記事 • Aug 23Does Crop Life Science (NSE:CLSL) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹53.55, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 35x in the Chemicals industry in India.
お知らせ • Aug 21Crop Life Science Limited, Annual General Meeting, Sep 21, 2024Crop Life Science Limited, Annual General Meeting, Sep 21, 2024, at 15:30 Indian Standard Time.
お知らせ • Jul 31Crop Life Science Limited Appoints Ashish Mahendersingh Chaudhary as Company Secretary and Compliance OfficerCrop Life Science Limited appointed Ms. Ashish Mahendersingh Chaudhary has been appointed as Company Secretary and Compliance Officer of the Company, effective from July 31, 2024. Date of Birth: 08/06/1999.
分析記事 • Jul 05Crop Life Science Limited's (NSE:CLSL) Shares Bounce 27% But Its Business Still Trails The MarketCrop Life Science Limited ( NSE:CLSL ) shares have had a really impressive month, gaining 27% after a shaky period...
Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹4.02 (vs ₹3.39 in FY 2023)Full year 2024 results: EPS: ₹4.02 (up from ₹3.39 in FY 2023). Revenue: ₹2.01b (up 52% from FY 2023). Net income: ₹60.4m (up 48% from FY 2023). Profit margin: 3.0% (down from 3.1% in FY 2023). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹43.00, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 29x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹38.25, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 28x in the Chemicals industry in India.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended February 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Market cap is less than US$10m (₹781.6m market cap, or US$9.43m). Minor Risk Latest financial reports are more than 6 months old (reported February 2023 fiscal period end).
Valuation Update With 7 Day Price Move • Dec 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹48.80, the stock trades at a trailing P/E ratio of 17.6x. Average trailing P/E is 30x in the Chemicals industry in India.
お知らせ • Nov 22Crop Life Science Limited, Annual General Meeting, Dec 13, 2023Crop Life Science Limited, Annual General Meeting, Dec 13, 2023, at 11:00 Indian Standard Time. Location: 209, Primate, Near Judges Bunglow Cross Road Bodakdev Ahmedabad India Agenda: To receive,consider and adopt the Audited Standalone Financial Statement of the Company for the Financial Year ended 31st March, 2023 together with report of the Board of Directors & Auditors thereon; to appoint a Director in place of Mr. Chunilal Samajubhai Virolia; to consider and if thought fit to pass the following resolution with or without modification as Special Resolution; to ratify the remuneration of the Cost Auditors for the financial year ending March 31st, 2024; to approve to make investments, give loans, guarantees and provide securities under Section 186 of the Companies Act, 2013; to approve transactions under Section 185 of the Companies Act, 2013; and to Related Party Transaction for The Financial Year 2023-24.
お知らせ • Aug 31Crop Life Science Limited has completed an IPO in the amount of INR 267.28 million.Crop Life Science Limited has completed an IPO in the amount of INR 267.28 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,440,000 Price\Range: INR 52 Discount Per Security: INR 0.4888 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 260,000 Price\Range: INR 52 Discount Per Security: INR 0.4888 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,440,000 Price\Range: INR 52 Discount Per Security: INR 0.4888 Transaction Features: Regulation S
